Identification of 6-Anilino Imidazo[4,5-c]pyridin-2-ones as Selective DNA-Dependent Protein Kinase Inhibitors and Their Application as Radiosensitizers. [PDF]
Hong CR+11 more
europepmc +1 more source
Promises of Protein Kinase Inhibitors in Recalcitrant Small-Cell Lung Cancer: Recent Scenario and Future Possibilities. [PDF]
Tiwari A+7 more
europepmc +1 more source
Salt-inducible kinases (SIKs) regulate TGFβ-mediated transcriptional and apoptotic responses [PDF]
A Rojas-Fernandez+63 more
core +2 more sources
Application of parallel artificial membrane permeability assay technique and chemometric modeling for blood-brain barrier permeability prediction of protein kinase inhibitors. [PDF]
Jovanović M+5 more
europepmc +1 more source
Targeting the trypanosome kinetochore with CLK1 protein kinase inhibitors. [PDF]
Saldivia M+22 more
europepmc +1 more source
Related searches:
Non-kinase targets of protein kinase inhibitors
Nature Reviews Drug Discovery, 2017Kinome-wide profiling platforms have comprehensively identified the relevant kinases that are targeted by numerous protein kinase inhibitors. However, recent projects have begun to discover non-kinase targets of kinase inhibitors. These non-kinase targets can contribute to the desired or undesired activities of inhibitors, or act as silent bystanders ...
Lenka Munoz
openaire +5 more sources
Irreversible Protein Kinase Inhibitors
Current Medicinal Chemistry, 2011Targeting cancer with small molecule irreversible inhibitors of kinases represents an emerging challenge in drug discovery. Irreversible inhibitors bind to kinase active site in a covalent and irreversible form, most frequently by reacting with a nucleophilic cysteine residue, located near the ATP binding pocket.
GARUTI, LAURA+2 more
openaire +4 more sources
Protein kinase inhibitors in melanoma
Expert Opinion on Pharmacotherapy, 2013The most commonly mutated oncogene identified to date in melanoma is BRAF (∼ 50%), an upstream mediator of the mitogen-activated protein kinase (MAPK) pathway. Recently, BRAF-kinase inhibitors as well as MEK-kinase inhibitors were introduced into the clinics.Substantial Phase II and III clinical trials were searched in patients with advanced melanoma ...
Claus Garbe+2 more
openaire +3 more sources
Inhibitors of protein kinases and phosphatases
Trends in Biochemical Sciences, 1994Inhibitors of eukaryotic protein kinases and phosphatases are a chemically diverse array of natural and synthetic compounds, including medicines, potions and poisons. These substances are valuable pharmacological probes and affinity ligands for the kinases and phosphatases of signalling pathways, enhancing our knowledge of the cellular effects of the ...
MacKintosh, Carol, MacKintosh, Robert W.
openaire +4 more sources